Articles Tagged With: Vancomycin
-
Fidaxomicin Is More Clinically Effective than Vancomycin for C. difficile Infection
There is a lack of real-world data on using fidaxomicin for Clostridioides difficile infection (CDI). A retrospective, single-center study found that treatment of CDI with fidaxomicin leads to reduced clinical failure compared to oral vancomycin.
-
Clostridioides difficile: Reduced Susceptibility to Vancomycin?
Many sites have been reluctant to prescribe fidaxomicin as the first-line agent, despite fairly robust evidence indicating its efficacy relative to vancomycin in preventing recurrences. We still cannot predict who will do well with vancomycin and which patients are likely to relapse or to do more poorly. The gradual emergence of Clostridioides difficile with reduced vancomycin susceptibility may contribute to adverse outcomes when using this agent.
-
Fidaxomicin Is More Clinically Effective than Vancomycin for C. difficile Infection
There is a lack of real-world data on using fidaxomicin for Clostridioides difficile infection (CDI). A retrospective, single-center study found that treatment of CDI with fidaxomicin leads to reduced clinical failure compared to oral vancomycin.
-
Fidaxomicin vs. Oral Vancomycin for Clostridioides difficile Infection in Patients Receiving Concomitant Antibiotics
This open-label, randomized trial of patients with Clostridioides difficile infection receiving concomitant antibiotics found no difference in clinical cure between fidaxomicin and oral vancomycin.
-
Clostridioides difficile and Reduced Vancomycin Susceptibility
Growth inhibition of Clostridioides difficile isolates from patients in Houston and Nairobi is requiring increasing concentrations of vancomycin, raising concerns about therapeutic efficacy.
-
Clostridioides difficile Infection: Guideline Update
Fidaxomicin is preferred over vancomycin for initial and recurrent cases. Bezlotoxumab is recommended in many cases of recurrent infection and initial infection in patients at high risk of recurrence.
-
Does the Addition of IV Metronidazole Improve Outcomes of Severe Clostridioides difficile Infection?
These studies indicate that the addition of intravenously administered metronidazole in the treatment of severe Clostridioides difficile infection is unwarranted.
-
Evaluation of 2020 Vancomycin Guidelines: Highlights, Limitations, and Obstacles
The key change from the 2009 vancomycin guidelines is the switch from trough-based to area under the curve (AUC)-based dosing and monitoring. This article will highlight key differences between the 2009 and 2020 guidelines, limitations of the new guidelines, and implementation issues.
-
Combination Therapy of MRSA Bacteremia Was Not Beneficial in a Randomized Clinical Trial
In a randomized clinical trial conducted at 27 hospitals in four countries, researchers found that the addition of an antistaphylococcal beta-lactam to vancomycin or daptomycin (99% received vancomycin) did not lead to improved outcomes in MRSA bacteremia. The trial was stopped early because of safety concerns, including a higher risk of acute kidney injury in the combination group.
-
Fulminant Clostridioides difficile Infection: Hold the IV Metronidazole?
The combination of oral vancomycin and intravenous metronidazole is not superior to vancomycin alone in the treatment of fulminant infection due to Clostridioides difficile.